Fig 1: Ang-(1–7) treatment suppressed the expression of Beclin-1 protein and secretions of IL-25 and IL-33 in the IL-13-treated BEAS-2B cells. BEAS-2B cells were transfected with control siRNA or ATG5 siRNA, and then treated with IL-13 for 24 h. The IL-13-treated cells were treated with 20 µM Ang-(1–7) for 24 h, and the PBS treatment was as a control treatment. A Cell viability in different groups was measured using a CCK-8 kit. B Expression of Beclin-1 protein was measured using Western blotting. C Secretion of IL-25 and IL-33 was measured using ELISA kits. ns: no significance. *p < 0.05, **p < 0.01
Fig 2: Ang-(1–7) suppressed the results of ATG5 overexpression in IL-13-induced BEAS-2B cells. The BEAS-2B cells were transfected with ATG5 cDNA or vector control, and treated with IL-13 for 24 h. The ATG5 cDNA-transfected or vector control-transfected cells were treated with 20 µM Ang-(1–7) treatment. A Expression of Beclin-1 protein was measured using Western blotting. B Secretion of IL-25 and IL-33 was measured using ELISA kits. **p < 0.01
Fig 3: IgE and inflammatory cytokine levels between HRV-positive and HRV-negative groups in non-AIT AR subjects. (A) Total serum IgE levels in HRV-positive group (n = 54) vs HRV-negative group (n = 49). (B) Total nasal lavage IgE levels in HRV-positive group (n = 54) vs HRV-negative group (n = 49). (C–F) Nasal lavage levels of CXCL13, IL-25, IL-4, and IL-5 cytokines in HRV-positive group (n = 54) vs HRV-negative group (n = 49). Data are presented as the mean ± SD. *P < 0.05 based on two-tailed Mann–Whitney U-tests (A and B) and two-tailed t-test (C–F).
Supplier Page from Abcam for Human IL-25 ELISA Kit